Anavex Life Sciences Corp (AVXL)

[Hoskuld]

Yes. As another poster wrote, other P3 trials have had to be large in order to get enough safety data and to try to get N high enough that even a small effect would generate a statistically significant p number. In the case of 2-73, if 509 is not enough to generate a good sized effect with a very low p number then it doesn't deserve approval. And there are collectively enough patients being dosed with 2-73 across several indications to provide strong safety data.